Literature DB >> 2061106

Prognosis following local recurrence in the conservatively treated breast cancer patient.

B G Haffty1, D Fischer, M Beinfield, C McKhann.   

Abstract

At Yale-New Haven Hospital conservative treatment of early stage breast carcinoma with lumpectomy and radiation therapy has been used with increasing frequency since the 1960s. We have reviewed our experience with specific reference to prognosis following local recurrence. Between January 1962 and December 1984 a total of 433 patients were treated with conservative surgery and radiation therapy using standard techniques. As of December 1989, with minimum evaluable follow-up of 5 years and a median follow-up of 8.21 years, there have been a total of 50 ipsilateral breast recurrences resulting in a 5-year actuarial breast recurrence rate of 8%. Extent of disease at the time of local recurrence was clinically categorized as localized (less than 3 cm without dermal involvement) or diffuse (greater than 3 cm and/or with dermal involvement). Seventy-two percent of the recurrences were at or near the original tumor site whereas 28% recurred elsewhere in the breast. At a median follow-up post recurrence of 5.0 years (range 0.3-16.9 years), the 5-year actuarial survival for breast recurrences was 59% and the 5-year disease-free survival was 65%. A number of clinical and pathological features at the time of original diagnosis as well as at the time of local recurrence were tested as possible prognostic indicators for survival following local recurrence. By univariate analysis, significant factors associated with survival following local recurrence included extent of local disease at the time of recurrence (p less than .01), time to local recurrence (p less than .03), with later recurrences doing better, and site of local recurrence (p less than .01), with recurrences elsewhere in the breast doing better. We conclude from this large single institutional experience with a median follow-up post-recurrence of over 5 years that patients experiencing a local recurrence in the conservatively treated breast have a relatively favorable prognosis. The prognostic factors correlating with survival and implications regarding adjuvant systemic therapy at the time of local recurrence are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 2061106     DOI: 10.1016/0360-3016(91)90774-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Comment on 'Breast deformity, its correction, and assessment of breast conserving surgery'.

Authors:  N Handel
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.

Authors:  Stephanie M Cohen; Ridhwi Mukerji; Shuang Cai; Ivan Damjanov; M Laird Forrest; Mark S Cohen
Journal:  Am J Surg       Date:  2011-10-08       Impact factor: 2.565

3.  Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.

Authors:  Min Yi; Thomas A Buchholz; Funda Meric-Bernstam; Isabelle Bedrosian; Rosa F Hwang; Merrick I Ross; Henry M Kuerer; Sheng Luo; Ana M Gonzalez-Angulo; Aman U Buzdar; W Fraser Symmans; Barry W Feig; Anthony Lucci; Eugene H Huang; Kelly K Hunt
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

4.  NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence.

Authors:  Douglas W Arthur; Kathryn A Winter; Henry M Kuerer; Bruce G Haffty; Laurie W Cuttino; Dorin A Todor; Nicole L Simone; Shelly B Hayes; Wendy A Woodward; Beryl McCormick; Randi J Cohen; Walter M Sahijdak; Daniel J Canaday; Doris R Brown; Adam D Currey; Christine M Fisher; Reshma Jagsi; Julia White
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-18       Impact factor: 7.038

5.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Authors:  Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; José Manuel Baena Cañada; Beat Thürlimann; Elizabeth Murray; Eleftherios P Mamounas; Charles E Geyer; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Norman Wolmark; Irene L Wapnir
Journal:  Lancet Oncol       Date:  2014-01-16       Impact factor: 41.316

6.  Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.

Authors:  Irene L Wapnir; Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Eleftherios P Mamounas; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2008-09-11       Impact factor: 5.344

7.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

Authors:  Stewart J Anderson; Irene Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Jong-Hyeon Jeong; Charles E Geyer; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

8.  Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).

Authors:  Heather B Neuman; Jessica R Schumacher; Amanda B Francescatti; Taiwo Adesoye; Stephen B Edge; David J Vanness; Menggang Yu; Daniel McKellar; David P Winchester; Caprice C Greenberg
Journal:  J Clin Oncol       Date:  2018-01-31       Impact factor: 44.544

9.  Prognostic factors in 77 curative chest wall resections for isolated breast cancer recurrence.

Authors:  Carmen C van der Pol; Albertus N van Geel; Marian B E Menke-Pluymers; Paul I M Schmitz; Titia E Lans
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

10.  Recurrence dynamics does not depend on the recurrence site.

Authors:  Romano Demicheli; Elia Biganzoli; Patrizia Boracchi; Marco Greco; Michael W Retsky
Journal:  Breast Cancer Res       Date:  2008-10-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.